Dexcom announced the first and only randomized, controlled study focusing solely on the benefit of continuous glucose monitoring (CGM) for diabetes patients on multiple daily injections (MDI) insulin therapy. The DIaMonD study (Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes) is the first-of-its-kind study that demonstrates the impact of CGM on A1C and hypoglycemia in participants on a multiple daily injection insulin regimen. Published in the January 24 issue of the Journal of the American Medical Association (JAMA), the study showed Dexcom CGM System users on MDI achieved a 1% average A1C reduction after 24 weeks of regular use, compared to baseline. In addition to better glucose control, participants also increased time spent in target range and spent less time in hypoglycemia and hyperglycemia when they used a Dexcom CGM System compared to those who used only a standard meter to monitor their glucose. The DIaMonD study included 158 adult participants with type 1 diabetes on MDI. At 24 weeks, the average A1C reduction (a measure of average blood glucose over a 2-3 month period) in subjects assigned to the CGM group (n=105) was 1% compared to baseline. Subjects in the SMBG control group showed only a 0.4% reduction (n=53); (p<0.001). The CGM System used in the study was the Dexcom G4 PLATINUM CGM System with Software 505, made by DexCom, Inc. The company's current product, the Dexcom G5 Mobile CGM System, also uses this software. A subset of subjects who were considered uncontrolled-an A1C greater than 8.5%-saw a 1.3% reduction in A1C from baseline at week 24.